<DOC>
	<DOCNO>NCT01096238</DOCNO>
	<brief_summary>In spring 2009 , recently emerge novel influenza A ( H1N1 ) virus first identify Mexico USA continue spread globally . The rapid global spread novel influenza A ( H1N1 ) 2009 virus prompt World Health Organization ( WHO ) , 11 June 2009 , declare first influenza pandemic 41 year . In Taiwan , clinical study assess immunogenicity safety Influenza Virus Vaccine , AdimFlu-S ( A/H1N1 ) , healthy volunteer already complete . In previous study , find single 15 mcg HA dose AdimFlu-S ( A/H1N1 ) vaccine induces protective immune response adult , include &gt; 60 year age ( &gt; 70 % ) . Our current study aim follow-up subject receive Influenza Virus Vaccine , AdimFlu-S ( A/H1N1 ) , six month ago . These subject ' serum sample test anti-hemagglutinin ( HA ) antibodies hemagglutination inhibition ( HAI ) . The seroconversion define post-vaccination serum HAI titer least 1:40 subject seronegative pre-vaccination four-fold great increase HAI titer subject seropositive pre-vaccination serum . The immunogenicity Influenza Virus Vaccine , AdimFlu-S ( A/H1N1 ) , adult half year analyze discuss among subject serum HAI titer least 1:40 least 3 week AdimFlu-S ( A/H1N1 ) injection .</brief_summary>
	<brief_title>Follow-up Immunogenicity Influenza Virus Vaccine , AdimFlu-S ( A/H1N1 ) , Healthy Volunteers After 6 Months</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>subject serum HAI titer least 1:40 least 3 week AdimFluS ( A/H1N1 ) injection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>The immunogenicity Influenza Virus Vaccine , AdimFlu-S ( A/H1N1 ) , adult half year analyze discuss .</keyword>
</DOC>